• Clinical Trials - Pancreatic cancer

    Study Objective Contact
    A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined with nab-Paclitaxel Plus Gemcitabine Compared with nab-Paclitaxel Plus Gemcitabine in Subjects with Stage IV Previously Untreated Pancreatic Cancer [LCID Study Number: 2013-035] This protocol compares the effects of standard of care treatment (nab-paclitaxel and gemcitabine) to the standard of care plus PEGPH20 in patients with stage IV pancreatic cancer. This study is ongoing but no longer accepting new patients. Principal Investigator(s):
    Francis W. Nugent, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Erin H. Hartnett,
    Julie Roache.
    E2211: A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors [LCID Study Number: 2013-040] This protocol addresses whether the combination of temozolomide and capecitabine works better than temozolamide alone on advanced pancreatic neuroendocrine tumor cancer. Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Erin H. Hartnett,
    Kori D. Hesse.
    Molecular Analysis of Cancer [LCID Study Number: 2011-048] The purpose of this research is to discover molecular changes involved in cancer. We hope that a better understanding of these changes can improve cancer management. This research may include genetic and/or genomic analysis (tests to determine and compare your genetic sequence, or DNA). Some of the tissue we collect for our research may be submitted to the National Cancer Institute Cancer Genome Atlas Project. The goal of this project is to determine the genomic changes involved in more than 20 types of human cancer. Principal Investigator(s):
    Kimberly R. Christ, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Doreen L. Browne, ,CCRP,
    Jane S. Nalwalk,
    Linda M. Topjian.